The ideal gene therapy for metabolical liver disorders would target hepatocytes before the onset of disease and be durable, non-toxic and non-immunogenic. Early gestational gene transfer can achieve such goals. Here, we demonstrate that prenatal gene transfer of human Atp7b reduces liver pathology and improves biochemical markers in Atp7b À/À mice, a murine model of Wilson's disease (WD). Following prenatal injection of lentivirus vector containing the human Atp7b gene under the transcriptional control of a liver-specific promoter, the full-length ATP7B was detectable in mouse livers for the entire duration of experiments (20 weeks after birth). In contrast to a marked pathology in non-injected animals, livers from age-matched treated mice consistently demonstrated normal gross and histological morphology. Hepatic copper content was decreased in the majority of treated mice, although remaining copper levels varied. Improvement of hepatic copper metabolism was further apparent from the presence of copper-bound ceruloplasmin in the sera and normalization of the mRNA levels for HMG CoAreductase. With this approach, the complete loss of copper transport function can be ameliorated, as evident from phenotypical improvement in treated Atp7b À/À mice. This study provides proof of principle for in utero gene therapy in WD and other liver-based enzyme deficiencies.
Wilson's disease (WD) is an autosomal recessive disease of copper metabolism. Mutations in the Atp7b gene cause impairment of the ATP7B protein, a copper-transporting ATPase that normally acts in the hepatocyte to (i) incorporate copper into ceruloplasmin for export into the blood and (ii) sequester excess copper in apical vesicles for excretion into the bile. 1 In human WD, copper accumulates in several organs, particularly the liver and brain, causing progressive hepatic and neurological dysfunction. 2 Phenotypical presentation of WD is widely variable; the hepatic disease can take many forms and its severity does not always correlate with the degree of neurological findings. 2 Signs of disease are rarely present before 5 years of age, and in the first two decades of life, liver manifestations (unexplained liver failure or cirrhosis) predominate. 1 In the second or third decades of life, neurological and/or psychiatric symptoms become apparent. Only about 25% of patients will have both hepatic and neuropsychiatric involvement at the time of diagnosis. 2 The earliest symptoms of neurological WD include difficulty in speaking, drooling and clumsiness of the hands, often associated with a change in personality. The diagnosis can be made by a low serum ceruloplasmin (less than 20 mg dl À1 ) in addition to high hepatic copper content (exceeding 250 mg g À1 dry weight of liver; normal concentrations are less than 50 mg g À1 ) or the presence of Kayser --Fleischer rings on ophthalmological slit lamp exam. 1 However, none of these findings in isolation is sufficient to make the diagnosis. Histological findings are non-diagnostic and can mimic other liver diseases. The liver biopsy in early disease demonstrates microvesicular and macrovesicular steatosis, whereas in late disease, inflammation, advancing fibrosis and cirrhosis are present. Occasionally, WD can present as fulminant hepatic failure.
Current treatment requires lifetime adherence to medications (primarily the copper chelator, penicillamine), and side effects, including neurological worsening, pancytopenia, nephrotoxicity, polyneuropathy, optic neuritis, polymyositis, elastosis, arthritis or rash are seen in up to 70% of patients. 3 Expression of a functional gene in hepatocytes has the potential to prevent morbidity and alleviate both hepatic and neurological symptoms. 4 The treatment of WD in rodents has focused on cell and gene therapy. 5 --9 In the Long Evans Cinnamon rat model of WD, hepatocyte transplantation has demonstrated a therapeutic effect. 5 However, attempts at gene therapy for WD using adenoviral and lentiviral vectors to express human Atp7b in adult animals have had limited success. 6 --9 Adenoviral vectors efficiently transduce the liver, but expression is rapidly lost due to lack of integration and the host immune response. 4 Accordingly, adenoviral-mediated Atp7b gene expression achieved only a transient effect. 6, 7 Lentiviruses can integrate into the host genome and have long duration of expression. 4 However, when systemic delivery of lentivirus containing Atp7b was compared with transplantation of transduced hepatocytes, systemic therapy was found to be more effective but lacked tissue specificity and did not completely rescue the liver abnormalities. 8 Although Atp7b expression in transgenic mice achieves therapeutic effect, 9 the ideal clinical strategy would achieve efficient, permanent and liver-specific Atp7b expression.
Prenatal gene transfer has several advantages including fetal immunologic tolerance, increased vector particle to cell ratio, increased frequency of stem cells in all tissues and increased accessibility of stem cell populations, 10 presenting a unique opportunity for high efficiency gene transfer. As WD has an autosomal recessive pattern of inheritance and can be diagnosed prenatally, 11 in utero somatic gene therapy is a theoretical possibility. We have previously shown that early gestational gene transfer using lentiviral vectors produces a long-term, stable transduction of a number of tissues. 12 --17 Consequently, to explore the possibility of prenatal gene therapy for WD, we used an animal model and examined functional consequences of the in utero transfer of Atp7b.
Three rodent models of WD were available for our study. To ensure that all baseline ATP7B activity was absent, we chose the Atp7b À/À mouse model. These mice were generated by inserting early termination codons into the second exon of the Atp7b gene, which resulted in a truncated mRNA and complete loss of the ATP7B protein. 18 An advantage of these animals is the availability of morphological and biochemical data for the entire course of disease progression.
19 --22 By 6 weeks, copper accumulates in the livers of Atp7b À/À mice. 19 From 12 weeks, phenotypical and metabolical changes are observed, including gross morphological changes, loss of copper incorporation into ceruloplasmin and marked downregulation of cholesterol biosynthesis. Unlike the human disease, the Atp7b À/À mice do not replicate neurological WD. The highest level of copper accumulation and the most dramatic phenotype is seen in the livers of Atp7b À/À mice. Copper does accumulate in the brain, but to a much less significant degree, because ATP7A, another copper-transporting ATP-ase, is thought to compensate for the lack of ATP7B. 19 --22 In this study, we performed early gestational gene transfer of lentiviral vector containing the human Atp7b gene under the transcriptional control of a liver-specific promoter (LSP). Using this approach, we demonstrate phenotypical improvement in Atp7b À/À mice, including a decrease in liver copper levels, preservation of normal hepatic histology, restoration of copper incorporation into ceruloplasmin and improved cholesterol biosynthesis.
RESULTS

Animals' survival after in utero injection
In control experiments, using a green fluorescent protein (GFP) reporter vector in Balb/c mice, we observed 30 percent (21/69 fetuses) survival to at least postnatal day 7 after E10 intracardiac injections. With the targeting vector (LSP.GFP.huATP7B) in Atp7b mice, 29% (112/382) of fetuses survived, indicating the lack of significant toxic effects of ATP7B expression or noticeable strain differences. There was no difference in survival between these two groups (P ¼ 1.00, w 2 -test). Of the 112 survivors, there was no statistically significant difference in survival rate between Atp7b þ / þ , Atp7b þ /À, and Atp7b À/À mice for up to 6 months of age (P ¼ 0.94, w 2 -test).
Non-selective versus liver-specific expression of GFP after E10 intracardiac injection We first compared the ubiquitous modified myeloid proliferative sarcoma virus promoter (MND) promoter to the LSP. Following E10 intracardiac injection of MND.GFP, green fluorescence was seen in the heart, liver and bones ( Figures 1a --d ) from postnatal day 1 to at least 12 months of age (Figures 1b --d) . The LSP significantly increased tissue specificity. After E10 injection, hepatic GFP expression was enhanced, while expression was minimal to absent in non-hepatic tissues (Figures 1e --h ). GFP expression was maintained for 36 weeks, the duration of this study (Supplementary Figures S1a --f ).
E10 intracardiac injection with a targeting vector results in the expression of ATP7B in the liver Given the above results, only the LSP was used for gene transfer experiments in Atp7b À/À mice. To verify that the ATP7B protein was produced, frozen liver sections were immunostained with the antibody raised against human ATP7B. Human protein was detected in the animals injected with the targeting vector, while the antibody did not detect mouse Atp7b in the livers of wild-type or non-injected knockout mice. Representative images from injected 6-week-old mice demonstrate co-localization of GFP and ATP7B (Figure 2 ). Both proteins were expressed in injected animals from 4 to 20 weeks of age, the time-interval of our analysis. To further ascertain that the full-length ATP7B was being expressed, the size of expressed protein was determined by western blot. At all time points analyzed, ATP7B was present as a 165-kDa band (Figure 3a) .
Injected knockout mice display improved liver morphology compared with age-matched controls When analyzed at 14 and 20 weeks postnatally, normal gross and histological morphology was preserved in injected mice as compared with non-injected Atp7b À/À control mice (Figures 4a --j and 5a --f).
Expression. of ATP7B correlates with the decrease in hepatic copper content in injected animals To evaluate whether the expressed ATP7B improves copper distribution in the liver, copper was first detected by histological Rhodanine staining (Supplementary Figures S2a --h ). As expected, wild-type mice, including those injected, have low copper levels (see Figures 6a --c) and no Rhodanine staining. The knockout control livers at 14 and 20 weeks show clusters of red-stained copper. The injected knockout mice had no clusters of copper, but rather, rare single copper granules, suggesting that copper concentration was decreased or redistributed. To verify this conclusion more directly, liver copper content was determined by atomic absorption spectroscopy (Figures 6a --c) . In these experiments, we also examined animals of younger age to measure whether a decrease in copper, if observed, changes with time.
Among the 6-week-injected knockout mice assayed, 67% (4/6) showed significantly decreased copper when compared with noninjected controls (P ¼ 0.0001, unpaired two-tailed t-test) ( Figure 6a ). In all, two animals showed no change in copper levels despite the presence of ATP7B (verified by immunostaining, animal 152 is shown in Figure 4 ). Among the 14-week mice, 100% (6/6) injected knockout mice had lower absolute copper content than knockout controls, but the decrease was not as dramatic as at 6 weeks, nor was it statistically significant (P ¼ 0.18, unpaired twotailed t-test) (Figure 6b ). Among the 20-week mice, 100% (n ¼ 3) of injected knockout mice showed significantly decreased copper content when compared with non-injected controls (P ¼ 0.03, unpaired two-tailed t-test) (Figure 6c ).
Fractionization of livers for subcellular localization of copper In hepatocytes, accumulating copper is bound to cytosolic metallothioneins and/or sequestered in the membrane compartments (nucleus, mitochondria and lysosomes); ATP7B expression is expected to decrease cytosolic copper and increase the amount of copper in vesicles (membrane fraction). To explain the uniformly improved tissue histology in the injected mice observed despite variation in their hepatic copper content, we examined whether all injected animals have lower fraction of cytosolic copper compared with non-injected control.
Of the livers that we were able to fractionate, the results did not provide a clear answer. In the 6-week non-injected knockout mice, copper accumulates predominantly in the soluble (or cytosolic) fraction with a small amount (o100 ng mg À1 protein) in the insoluble (or membranous) fraction. 19 The injected 6-week-old knockout mice with low overall copper content had low amounts of copper in both soluble and membrane-bound compartments (Figure 7a ), consistent with overall improvement in their copper metabolism. However, in the two injected mice with high copper Figure 1 . GFP expression after E10 intracardiac injections. With a ubiquitous MND promoter, GFP targets the (a) heart, (b) liver, and (c, d) bones. In side by side histological comparison, the MND promoter transduces the (e) liver and (f) heart, whereas the LSP shows increased GFP expression in the (g) liver, but no GFP expression in the (h) heart. Scale bar for gross images ¼ 1 mm and for histological sections ¼ 50mm.
content, the results differed. In animal 152, more copper was in the membranous portion than would be expected for a knockout mouse suggesting increased copper sequestration in membranous compartments, whereas animal 293 had a profile very similar to an untreated knockout mouse. 19 Among the 14-week-old knockout mice, the two mice with low overall copper content (animals 160 and 191) had relatively equal amounts of copper in each compartment (Figure 7b ). By contrast, the mouse with high overall copper content (animal 290) had a profile much like an untreated knockout mouse, with the majority of copper in the soluble portion. For the 20-week-old knockout mice, both had relatively equal amounts of copper in each compartment (Figure 7c ).
Copper incorporation into ceruloplasmin is restored in treated mice
The above results demonstrated that restoration of liver morphology does not require removal of all copper from tissue and that additional tests are needed to evaluate the activity of expressed ATP7B and relevant liver functions. Consequently, we measured incorporation of copper into ceruloplasmin. In the Atp7b À/À mice, copper is not transported into the secretory pathway, and ceruloplasmin is secreted into the serum in the apo-form that lacks oxidase activity. In wild-type mice, both apo and copper-bound forms of ceruloplasmin can be detected by native gel-electrophoresis and western blot. 19 In this study, injected mice, at all time points, have both forms of ceruloplasmin, similar to the wild-type. Western blot data from the 6-week analysis are shown (Figure 3b ).
qRT-PCR for HMG CoA-reductase in 6-week livers Previous studies in Atp7bÀ/À knockout mice demonstrated that changes in the liver transcriptome, especially in cholesterol biosynthesis, were apparent at 6 weeks, before the appearance of noticeable morphological changes, 21 and persisted during the course of disease. One major change is a significant decrease in mRNA levels of HMG CoA-reductase, the enzyme involved in the Figure 2 . Frozen sections of liver were stained with GFP and ATP7B antibodies and analyzed by confocal microscopy. GFP is in green, ATP 7B in red. This ATP7B antibody only recognizes the human protein, not the innate mouse protein. Representative images of 6-week injected mice are shown. ATP7B and GFP colocalized in the same cells.
rate-limiting step in de novo cholesterol biosynthesis. Therefore, we analyzed 6-week livers for HMG CoA-reductase mRNA levels by qRT-PCR. Enzyme transcript in the non-injected knockout mouse was half that of the wild-type mouse (Figure 8 ). Among the injected knockout mice, normalization and further increase in HMG CoA-reductase expression was observed in 83% (5/6). Coincidentally, the mouse that had persistently low HMG CoAreductase expression was animal 293, the same animal that had high copper content and a profile of copper distribution similar to a non-injected knockout control.
Liver function tests in the aged mouse To determine the long-term effect of human ATP7B on liver function, we measured serum liver enzymes in an injected knockout mouse at 36 weeks of age. We found no significant differences in standard liver enzyme or bilirubin levels among the treated knockout as compared with 36-week-old wild-type controls (data not shown).
DISCUSSION
In this study, we demonstrate proof in principle for the prenatal prevention of WD. Using lentivirus-mediated early gestational gene transfer to a mouse model of WD, we attained stable human ATP7B expression, preservation of normal gross and histological liver anatomy, decreased copper content, restoration of the copper-bound form of ceruloplasmin and improved lipid biosynthesis.
Achieving liver-specific expression was an important aim of this project. Our early gestational intracardiac injection results in transduction of several mesodermally derived stem cell populations. Use of a LSP allowed liver transduction with a marked reduction of expression in other tissues. The stability of protein expression was maintained over the 36 week study duration and was well tolerated by recipient mice. The observed mortality was related to the intracardiac injection technique rather than the transgene.
The ATP7B gene transfer clearly had a beneficial effect in this study. Treated knockout mice showed no signs of gross pathology at any age, and increased liver HMG CoA-reductase confirmed improvement of lipid biosynthesis. However, analysis of copper concentration and distribution revealed unexpected complexity of copper homeostasis in the liver. Copper content in treated knockout livers was decreased in the majority of mice independent of age, but reduction in copper content was not uniform. The most dramatic decrease was seen at 6 weeks of age, while subsequently copper export from the liver appeared less efficient. Furthermore, some animals did not show significant reduction in their copper content. These effects are not due to the absence or disappearance of ATP7B expression, which was verified both by immunohistochemistry and western blot.
It is also clear that the expressed ATP7B was, at least partially functional in all animals, because copper was transported into the secretory pathway and incorporated to ceruloplasmin. In the noninjected animals, the largest fraction of accumulated copper was in the cytosol, whereas in the majority of ATP7B-expressing animals the proportion of cytosolic copper was decreased and Figure 3 . To confirm protein expression, we performed a western blot for ATP7B in the liver (a). Here, we used an antibody that recognizes both human and mouse ATP7B. Representative samples are shown. WT and het controls have a band at 165 kDa, whereas knockout controls do not. All of the injected mice were found to have a band at 165 kDa. To confirm that the human ATP7B had some function in the mouse hepatocyte, we looked for restoration of the copper-bound form of ceruloplasmin (holo-ceruloplasmin) in the serum with native western blot (b). The WT and het mice have both copper-and non-copper-bound forms of ceruloplasmin, whereas the KO control only has a band for the non-copper-bound form (apo-ceruloplasmin). At all time points, all of the injected knockout mice had both forms. Results from the 6-week-old mice are shown here. À1 dry weight. Black denotes control wild-type mice and gray denotes control knockout mice. The copper content in wild-type controls and injected wild-type mice was consistently less than 50 ng mg À1 (a). Among the 6 week injected knockout mice, 63% (4/6) had significantly decreased copper content (P ¼ 0.0001) (a). All mice assayed at 14 weeks had lower absolute copper content than knockout controls, but the data were not significant (P ¼ 0.18) (b). Among the 20 week mice, there was a statistically significant (P ¼ 0.03) decrease in copper content compared with knockout controls (c).
more copper was associated with the membranous compartments (presumably sequestered within the vesicles or lysosomes, although this remains to be formally demonstrated). A potential explanation for apparent inconsistencies relates to the fact that the efficient removal of copper from the liver requires the ability of ATP7B to traffic from the trans-Golgi network to the apical vesicles where ATP7B sequesters copper for further excretion into the bile. 23, 24 Thus, if the precision of ATP7B targeting or trafficking is insufficient (that is, ATP7B stays in the trans-Golgi network or is mis-localized to incorrect vesicles) then copper will still be sequestered (and no longer able to produce toxic effects), but elimination of copper from the liver will be slow.
A total of two observations are consistent with this idea. First, close examination of ATP7B staining in animals 163 and 152 (that have markedly different copper retention) illustrates that although both animals have detectable ATP7B, their patterns of ATP7B distribution are not identical (Figure 4) . Animal 152 has a more concentrated staining, which may reflect its inability to exit the trans-Golgi network and/or partial aggregation due to high expression. In the future, it would be important to carry out a detailed comparison of ATP7B targeting within hepatocytes using different organelle markers and correlate the ATP7B localization with the rates of copper exports into the bile.
Another observation suggesting that copper, although not fully removed, could be sequestered and thus not bioavailable is the increase in the amount of transcript for HMG CoA-reductase (Figure 8 ). The levels of this enzyme depend on bioavailable copper: they are diminished when copper is in excess and elevated when copper is limiting. 25 It is interesting that animal 152 that shows significant copper sequestration in the membranous compartment also shows a level of HMG CoA-reductase mRNA that exceeds the wild-type, that is, as if this animal is copper deficient. These observations emphasize, what has been suspected from many clinical reports, that the intracellular form and localization of copper is more important for overall liver function than the total copper content. 26 Despite our inability to normalize copper content in every injected mouse, the results are encouraging. An important consideration in this disease is what constitutes a 'cure'. As with any murine model, WD in mice does not exactly replicate human disease. Copper levels may not be the best measure of morbidity given that the detrimental effects of copper on the hepatocyte are still not fully understood. 20 Our data suggest that a partial, but incomplete correction of liver copper content was sufficient to alleviate many parameters of liver injury in all mice. The absence of gross and histological pathology, the restoration of holoceruloplasmin and lipid biosynthesis and the lack of liver transaminase elevation were all a result of human ATP7B expression in the knockout mice.
Although our approach is novel, the methodology needs to be further improved before clinical application and an analogous strategy would not be feasible clinically at this time. E10 in the mouse corresponds to B8 --9 weeks human gestation, 27 when the small size of the heart and the high mortality associated with an intracardiac injection would not be acceptable. At this early gestational age, however, vessels on the surface of the placenta or the cord itself might be accessible using a fetoscopic approach. Advances in fetoscopy will likely allow less invasive access to such vessels in the near future. It may also be possible to target the human fetal liver at a later gestational time point using currently feasible access techniques. As there are species-specific differences in vector tropism and distribution of transduction, it is unknown whether optimal timing in the human fetus would be analogous to that in the murine model. If a window of 8 --9 weeks proved to be optimal clinically, there would also be limitations of the timing of injection relative to the timing of prenatal diagnosis. Prenatal diagnosis of WD has been described as early as 12 weeks gestation, 11 so methods for earlier diagnosis would need to be developed. If earlier prenatal diagnosis can be achieved, it could be targeted toward those families with a genetic predisposition for WD, as their offspring would be the highest at risk for the disease.
In conclusion, this study demonstrates proof in principle for the prenatal prevention of a liver-based enzyme deficiency. WD can be diagnosed prenatally and is an appealing target for prenatal prevention. Using early gestational intravascular gene transfer, we showed that expression of a human transgene in Atp7bÀ/À mice could be liver-targeted, non-toxic and of long duration. Although the treated mice showed variations in liver copper content, the majority demonstrated decreased indices of disease. These data offer encouraging support for the future application of prenatal gene therapy as an alternative treatment for single-gene defect diseases.
MATERIALS AND METHODS Animals
The generation of Atp7b À/À mice on the hybrid C57BL Â 129S6/SvEv background was previously described. 18 Animals were housed in the Laboratory Animal Facility of the Colket Translational Research Building at The Children's Hospital of Philadelphia (CHOP). Mice were maintained in sterilized plastic micro isolator cages and given sterilized standard laboratory chow and tap water ad libitum. Mice were genotyped at 3 weeks of age and Atp7b null mice identified according to the original protocol. 18 Heterozygous animals were mated for 12 --18 h to achieve accurate time-dated pregnancies and the day of removal of male mice was considered E0. All experimental protocols were approved by The Institutional Animal Care and Use Committee at Children's Hospital of Philadelphia, and followed guidelines set forth in the 'Guide for Care and Use of Laboratory Animals' by the National Institutes of Health.
In utero injection technique
Time-dated Atp7b heterozygous females underwent intracardiac injection at E10 using the Vevo 2100 system (Visualsonics, Toronto, Canada). Pregnant mice were anesthetized and the surgical procedure was performed as previously described 12 with some modifications. Fetuses were scanned using a 30 --70-MHz probe and were positioned to get a clear view of the beating heart in B-mode. Under two-dimensional visualization, the micropipette tip was advanced through the uterine wall into the amniotic space. To ensure that the pipette was in the correct x-y plane, the tip was then advanced until it created an indentation in the myometrium. The wall of the heart was then punctured and the pipette tip positioned within the cardiac lumen. As liquid vector was injected into the lumen, it could be seen mixing with the more hyperechoic blood before being circulated. If the first 70 nl of liquid vector could not be visualized, the tip of the needle was repositioned before further injection. For each fetus, 350 --700 nl of vector suspension was injected with an automated syringe. To avoid error, the injections were performed by a single experienced technician. The procedure time was limited to 30 min, from incision until closure.
Lentiviral vector design
Starting materials for generating a self-inactivating human immunodeficiency virus type 1-based vector were provided by I. Verma (Salk Institute, La Jolla, CA, USA). 28 Modifications of the CS-CG vector included deletion of the remaining right U3 region except for 23 nucleotides downstream of the 3 0 ppt, deletion of the residual envelope and ancillary gag/pol sequences, insertion of the central DNA FLAP, insertion of the Rev response element and insertion of the Woodchuck hepatitis virus posttranscriptional regulatory element, which is modified, eliminating the initiation codon for the Woodchuck hepatitis X protein. For the MND.GFP vector, the enhanced GFP (Clontech Laboratories, Palo Alto, CA, USA) was located downstream of the MND U3 promoter, 29 modified so that all stop codons from the transcription start site to the translation initiation site were removed.
For the targeting vector, total RNA extracted from the enterocyte line, Caco-2 was used as a template for constructing a cDNA library following standard molecular biology protocols. The primer-specific PCR was used to amplify the 3 0 -terminal region from ATCC Clone 11048566 (GenBank BC11700). Similarly, primer-specific PCR was use to generate a clone containing the 5 0 -end of the ATP7B cDNA molecule from the Caco-2 library. The complete cDNA ATP7B clone was assembled by strand overlap PCR extension, 30, 31 cloned and sequenced. The enhanced GFP and the ATP7B molecule, identical to the coding sequence of human isoform a (GenBank reference sequence NM_000053.2), were inserted into the HIV-1-based transfer vector, a modified FG12 plasmid, 32 under the transcriptional control of a LSP, which contained elements of apolipoprotein E and alpha-1 antitrypsin, making it hepatocyte specific. 33 The transgene cassette contained the enhanced green fluorescent protein, eGFP reporter (Clontech) or both the reporter and the full-length ATP7B cDNA molecule. Bicistronic expression was achieved by inserting the therapeutic gene in-frame with the eGFP cDNA and the TaV sequence, a cis-acting hydrolase element derived from Thosea asigna virus. Viral vectors, pseudotyped with the vesicular stomatitis virus-G protein envelope, were generated using three plasmid co-transfection in 293 T cells, and viral supernatants were concentrated and titered as previously reported. 34 Viral titers ranged from 1 Â 10 9 to 3 Â 10 10 viral particles per milliliter viral supernatant injected for the MND.GFP vector and 1 --4 Â 10 9 for the LSP.ATP7B.GFP vector.
Gross analysis of GFP expression
Gross tissues were analyzed for GFP expression by stereoscopic fluorescence microscopy (MZ16FA; Leica, Heerburg, Switzerland). An exposure time of 1 s was used for all photographs.
Histological analysis of paraffin embedded sections
After killing the mice, livers were fixed in neutral buffer formalin (Sigma, St Louis, MO, USA), transferred to the histoprocessor (TP 1050, Leica) overnight, and embedded in paraffin using a Sakura Tissue-Tek paraffin embedder (Sakura Finetek USA, Torrance, CA, USA). Paraffin sections at 4 mm thickness were obtained using a paraffin microtome (Leica RM 2030, Leica Microsystems, Wetzlar, Germany) and collected on Probe On slides (Fisher Scientific, Pittsburgh, PA, USA). For brightfield microscopy, sections were de-paraffined, rehydrated in distilled water and stained with either hematoxylin and eosin or rhodanine for copper. For rhodanine staining, sections were placed in a working solution (6 ml of 0.2% rhodanine and 94 ml of distilled water) at 37 1C for 18 h. The next day, slides were rinsed three times in acetate buffer solution (pH 8.0), then counterstained with Mayer's hematoxylin solution for 10 min, rinsed again three times in acetate buffer, dehydrated and cleared through 95% ethyl alcohol, absolute alcohol and xylene, and mounted with resinous medium to produce a red color for copper and a blue color for the nuclei. Slides were imaged using a Leica DMRBE Microscope (Leica Microsystems).
Immunohistochemistry
Livers were fixed in 4% formalin for 48 h, transferred to 20% sucrose, and then flash frozen at À80 1C for sectioning. Primary antibodies to GFP (rabbit anti-GFP, Invitrogen, Carlsbad, CA, USA) and ATP7B (rat anti-ATP7B) were used in 1:500 dilutions. Secondary antibodies, Alexa fluor 488 antirabbit and 555 anti-rats (Invitrogen) were used at a concentration of 1:1000.
Western blot for liver ATP7B
Pieces of liver were sonicated in 0. Native western blot for serum ceruloplasmin For analysis of ceruloplasmin, 1 ml of serum was solubilized with 0.1% SDS in 1 Â native sample buffer (Invitrogen) and water to a final volume of 10 ml. Samples were separated on a 4 --13% tris-glycine gel under non-reducing/non-denaturing conditions to separate the apoand copper-bound forms of ceruloplasmin. Proteins were transferred to Immobilon-P (Millipore, Bedford, MA, USA) and ceruloplasmin was detected using goat anti-human-ceruloplasmin antibody (Sigma Cat. No. C0911). HRP-conjugated donkey anti-goat antibody (Jackson, West Grove, PA, USA) was used as a secondary (antibody dilution 1:10 000). HRP was detected with SuperSignal West Pico Chemiluminescent Detection Reagent (Thermo Scientific, Rockford, IL, USA).
Copper measurements of dried livers
Tissue samples were dried in a vacuum oven (Fisher Scientific) at 70 1C. Dried tissues were weighed and dissolved in concentrated HNO 3 at 60 1C in a dry bath incubator (Fisher Scientific). The amount of copper present in the solution was determined by atomic absorption spectrometry using an AA-6650 atomic absorption spectrophotometer (Shimadzu Corp., Kyoto, Japan). Copper levels were normalized to the dry weight of the livers.
Copper distribution in subcellular compartments
Livers were thawed from À80 1C and 50 --100 mg pieces were homogenized in 500 ml of 0.1 mol l À1 sodium phosphate buffer (pH 7.5), 0.25 mol l À1 sucrose (buffer A) in a loose-fitting Dounce homogenizer (Sigma-Aldrich, St Louis, MO, USA). To measure the distribution of copper between cytosol and membrane compartments, the homogenate was centrifuged for 5 min at 500 Â g to remove crude cell debris and then at 125 000 Â g for 30 min. The supernatant was separated from the pellet, the pellet was resuspended in buffer A, and copper in both fractions was measured by atomic absorption spectrometry. Copper levels were normalized to the amount of protein in the homogenate, which was determined by the method of Lowry et al. 35 
RNA isolation and reverse transcription
After killing the mice, pieces of liver were stored in RNAlater (Ambion, Austin, TX, USA) at À20 1C until use. Total cellular RNA was isolated using the RiboPure Kit (Ambion), according to the manufacturer's instructions. Purity of RNA was measured using the Biophotometer Plus (Eppendorf, Hauppauge, NY, USA). First strand cDNA was prepared using the High Capacity Reverse Transcriptase Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
qRT-PCR for HMG CoA-reductase in 6-week livers Previously prepared cDNA was stored at À20 1C until use. Fluorescentlabeled HMG CoA-reductase and Act B (housekeeping gene) TaqMan probes were used (Applied Biosystems). The cDNA was pre-amped for the respective probes for 14 cycles. Each sample PCR run was performed in triplicate. Simultaneous PCR was performed for negative control samples containing master mix and probes as described above but no template DNA (15 wells per 96-well sample plate). Thermal cycling was performed on a Fast Real-Time Quantitative PCR machine (Applied Biosystems 7500 Software).
Liver function tests
Aged mice were bled and serum collected. Liver function tests were performed by Antech Diagnostics (Lake Success, NY, USA).
